Evaluation of corticoresistance in patients with thyroid eye disease and use of rituximab as a second-line treatment.Published in:Endocrine (1355008X), 2025, v. 87, n. 3, p. 1112, doi. 10.1007/s12020-024-04108-4By:Pekarova, Klara;Schovanek, Jan;Dohnal, Roman;Radvansky Jr, Martin;Karasek, David;Karhanova, MartaPublication type:Article